

Instructions for Authors 2020

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.


6. Authors should pay attention to the following points when writing an article for AR:
- The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
- they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.
- (Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2020 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

Volume 17, Number 1, January-February 2020

ISSN (online): 1790-6245



Published by the International Institute of Anticancer Research

Online ISSN: 1790-6245

General Policy

- **CANCER GENOMICS & PROTEOMICS (CGP)** welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.
- CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online only and open access with **Stanford University HighWire Press**. For more information please visit our website www.cgp.iiarjournals.org.
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
- **E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

● Selection of Recent Articles

Duplex DNA from Sites of Helicase-Polymerase Uncoupling Links Non-B DNA Structure Formation to Replicative Stress. C. AMPARO, J. CLARK, V. BEDELL, J.L. MURATA-COLLINS, M. MARTELLA, F. PICHIORRI, E.F. WARNER, M. ABDELHAMID, Z.A.E. WALLER, S.S. SMITH (*Duarte, CA, USA; Norwich, UK*)

Pazopanib Inhibits Tumor Growth, Lymph-node Metastasis and Lymphangiogenesis of an Orthotopic Mouse of Colorectal Cancer. G. ZHU, M. ZHAO, Q. HAN, Y. TAN, Y. SUN, M. BOUVET, S.R. SINGH, J. YE, R.M. HOFFMAN (*San Diego, CA; Frederick, MD, USA; Fuzhou, PR China*)

KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma. A. KITAGAWA, T. MASUDA, J. TAKAHASHI, T. TOBO, M. NODA, Y. KURODA, Q. HU, Y. KOUYAMA, Y. KOBAYASHI, S. KURAMITSU, K. SATO, A. FUJII, Y. YOSHIKAWA, H. WAKIYAMA, D. SHIMIZU, Y. TSURUDA, H. EGUCHI, Y. DOKI, M. MORI, K. MIMORI (*Oita; Osaka; Fukuoka, Japan*)

Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis. I. PANAGOPOULOS, L. GORUNOVA, I.M. RINVOLL JOHANNSDOTTIR, K. ANDERSEN, A. HOLTH, K. BEISKE, S. HEIM (*Oslo, Norway*)

Whole Transcriptomic Analysis of Apigenin-mediated Influence on TNF α Immuno-activated MDA-MB-231 Breast Cancer Cells. D. BAUER, E. MAZZIO, K.F.A. SOLIMAN (*Tallahassee, FL, USA*)

Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. J.-S. PEI, W.-S. CHANG, P.-C. HSU, C.-C. CHEN, Y.-T. CHIN, T.-L. HUANG, Y.-N. HSU, C.-C. KUO, Y.-C. WANG, C.-W. TSAI, C.-L. GONG, D.-T. BAU (*Taoyuan; Taichung, Taiwan, ROC*)

Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intraepithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma. A.-F.W. POWWER, L.C.G. VAN DEN EINDEN, M. VAN DER LINDEN, J.Y. HEHIR-KWA, J. YU, K.M. HENDRIKS, E.J. KAMPING, A. EIJKELENBOOM, L.F.A.G. MASSUGER, J. BULTEN, A.A.G. VAN TILBORG, J.A. DE HULLU, R.P. KUIPER (*Nijmegen; Utrecht, the Netherlands*)

Identification of Novel Prognosis and Prediction Markers in Advanced Prostate Cancer Tissues Based on Quantitative Proteomics. O.K. KWON, Y.-S. HA, A.Y. NA, S.Y. CHUN, T.G. KWON, J.N. LEE, S. LEE (*Daegu, Republic of Korea*)

BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. T. TSUKAMOTO, S. NAKAHATA, R. SATO, A. KANAI, M. NAKANO, Y. CHINEN, S. MAEGAWA-MATSUI, Y. MATSUMURA-KIMOTO, T. TAKIMOTO-SHIMOMURA, Y. MIZUNO, S. KUWAHARA-OTA, Y. KAWAJI, M. TANIWAKI, T. INABA, K. TASHIRO, K. MORISHITA, J. KURODA (*Kyoto; Miyazaki; Hiroshima, Japan*)

MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. U.H. WEIDLE, D. SCHMID, F. BIRZELE, U. BRINKMANN (*Penzberg, Germany; Basel, Switzerland*)

Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer. Z. SUN, S. CAI, C. LIU, Y. CUI, J. JI, W.G. JIANG, L. YE (*Cardiff, UK; Beijing, PR China*)

Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer. D. WATANABE, H. FUJII, N. MATSUHASHI, H. IIHARA, Y. YAMADA, T. ISHIIHARA, T. TAKAHASHI, K. YOSHIDA, A. SUZUKI (<i>Gifu, Japan</i>)	2379
Clinical Outcomes and Prognostic Factors of Patients With Esophageal Squamous Cell Carcinoma With Oligo-recurrence Treated With Radical Re-irradiation. C.-Y. LIN, H.-Y. FANG, M.-Y. LEIN, C.-C. LIN, L.-Y. BAI, M.-H. TSAI, C.-C. CHEN, T.-C. HSIEH, Y.-C. WANG, J.-A. LIANG, C.-C. LI, C.-R. CHIEN (<i>Taichung; Hsinchu, Taiwan, ROC</i>)	2387
Epidemiological Correlations Between Head and Neck Cancer and Hepatitis B Core Antibody Positivity. M. FUKUSHIMA KOMORI, T. KIMURA, S. KARIYA, T. ONODA, S. TAKEDA, N. MIZUKAWA, S. IIDA, Y. KIMATA, K. NISHIZAKI (<i>Okayama; Tamano, Japan</i>)	2393
Book Reviews	2405

Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer. T. NAKANO, Y. KADONO, H. IWAMOTO, H. YAEGASHI, M. IIJIMA, S. KAWAGUCHI, T. NOHARA, K. SHIGEHARA, K. IZUMI, A. MIZOKAMI (<i>Kanazawa, Japan</i>)	2291
The Preoperative Prognostic Nutritional Index Predicts the Development of Deep Venous Thrombosis After Pancreatic Surgery. T. IGUCHI, K. SUGIMACHI, Y. MANO, M. KONO, M. KAGAWA, T. NAKANOKO, H. UEHARA, M. SUGIYAMA, M. OTA, M. IKEBE, M. MORITA, Y. TOH (<i>Fukuoka, Japan</i>)	2297
Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer. S. KUBA, S. MAEDA, M. MATSUMOTO, K. YAMANOUCHI, T. IWATA, M. MORITA, C. SAKIMURA, R. OTSUBO, H. YANO, S. SATO, K. KANETAKA, T. NAGAYASU, S. EGUCHI (<i>Nagasaki, Japan</i>)	2303
Clinical Significance of Dynamic Neutrophil-lymphocyte Ratio Changes in Patients With Colorectal Cancer. N. ASHIZAWA, S. FURUYA, S. KATSUTOSHI, M. SUDO, H. AKAIKE, N. HOSOMURA, Y. KAWAGUCHI, H. AMEMIYA, H. KAWAIDA, S. INOUE, H. KONO, D. ICHIKAWA (<i>Yamanashi, Japan</i>).....	2311
Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy. M. HOFFMANN, D. REITZ, J. TAUGNER, O. ROENGVORAPHOJ, L. KÄSMANN, C. EZE, M. KARIN, C. BELKA, F. MANAPOV (<i>Munich, Germany</i>).....	2319
Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage. P. PETRANOVIĆ OVČARIČEK, A. FRÖBE, F.A. VERBURG, J. MURGIĆ, M. BOSAK BUTKOVIĆ, S. OVČARIČEK, B. MAŽURAN, B. KRUŠLIN, D. JAKOVČEVIĆ, Š. ŠOIPI, B. RUŽIĆ, M. MILOŠEVIĆ, D. KRILIĆ, M. FRANCESCHI, T. JUKIĆ (<i>Zagreb; Osijek, Croatia; Marburg, Germany</i>)	2323
Cholecystectomy as Part of Cytoreductive Surgery for Advanced Ovarian Cancer: Perioperative Outcomes. C.G. LIAKOU, N. AKRIVOS, B. KUMAR, T.J. DUNCAN, H.L. TURNBULL, J.J. NIETO, N. BURBOS (<i>Norwich, UK</i>)	2331
Short-term Outcomes Following Robotic-assisted Laparoscopic Surgery for Technically Demanding Rectal Cancer. M. NUMATA, K. KAZAMA, A. ONODERA, K. HARA, Y. ATSUMI, H. OKAMOTO, T. AOYAMA, H. TAMAGAWA, T. GODAI, H. SAEKI, N. YUKAWA, M. SHIOZAWA, Y. RINO, M. MASUDA (<i>Yokohama; Fujisawa, Japan</i>)	2337
Prediction of Sentinel Lymph Node Metastasis Using the Platelet-to-lymphocyte Ratio in T1 Breast Cancer. K. TAKADA, S. KASHIWAGI, Y. ASANO, W. GOTO, R. KOUHASHI, A. YABUMOTO, T. MORISAKI, M. SHIBUTANI, T. TAKASHIMA, H. FUJITA, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>).....	2343
Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer. S. ENDO, M. IKENAGA, T. YAMADA, S. TAMURA, Y. SASAKI (<i>Osaka, Japan</i>).....	2351
Postoperative Bleeding After Esophagectomy for Esophageal Cancer in Patients Receiving Antiplatelet and Anticoagulation Treatment. T. AOYAMA, Y. ATSUMI, K. HARA, K. KAZAMA, H. TAMAGAWA, A. TAMAGAWA, K. KOMORI, Y. MAEZAWA, K. KANO, I. HASHIMOTO, T. OSHIMA, M. MURAKAWA, M. NUMATA, N. YUKAWA, M. MASUDA, Y. RINO (<i>Yokohama, Japan</i>).....	2359
Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer. H. TAMAGAWA, T. AOYAMA, A. TAMAGAWA, K. KOMORI, Y. MAEZAWA, K. KANO, M. MURAKAWA, Y. ATSUMI, K. HARA, K. KAZAMA, M. NUMATA, T. OSHIMA, N. YUKAWA, M. MASUDA, Y. RINO (<i>Yokohama, Japan</i>).....	2365
Upfront Surgery for Small Intestinal Non-Hodgkin's Lymphoma. T. IIDA, H. NOZAWA, H. SONODA, K. TOYAMA, K. KAWAI, K. HATA, T. TANAKA, T. NISHIKAWA, K. SASAKI, Y. SHUNO, M. KANEKO, K. MURONO, S. EMOTO, H. ISHII, M. KUROKAWA, S. ISHIHARA (<i>Tokyo, Japan</i>).....	2373

The Influence of Neoadjuvant Chemoradiation for Middle and Lower Rectal Cancer on Anorectal Function. Y. HIRATA, H. NOZAWA, K. KAWAI, K. HATA, T. TANAKA, T. NISHIKAWA, K. SASAKI, M. KANEKO, S. EMOTO, K. MURONO, H. SONODA, S. ISHIHARA (<i>Tokyo, Japan</i>)	2199
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. M. SVATON, M. ZEMANOVA, P. ZEMANOVA, J. KULTAN, O. FISCHER, J. SKRICKOVA, L. JAKUBIKOVA, M. CERNOVSKA, M. HRNCIARIK, M. JIROUSEK, J. KREJCI, D. KREJCI, O. BILEK, J. BLAZEK, K. HURDALKOVA, M. BARINOVA, B. MELICHAR (<i>Pilsen; Prague; Olomouc; Brno; Hradec Kralove, Czech Republic</i>).....	2209
Prevalence of Cervico-vaginal High-risk HPV Types and Other Sexually Transmitted Pathogens in Anogenital Warts Patients. D. MORTAKI, E. TSITSOPOULOS, E. LOUIZOU, E. TSIAMBAS, D. PESCHOS, V. SIOULAS, A. GALANOS, A. TAGKA, S. GREGORIOU, A. STRATIGOS, D. RIGOPOULOS, E. NICOLAIDOU (<i>Athens; Ioannina, Greece</i>)	2219
Primary Hepatic Carcinosarcoma Composed of Hepatocellular Carcinoma, Cholangiocarcinoma, Osteosarcoma and Rhabdomyosarcoma With Poor Prognosis. L. LIU, E. AHN, K. STUDEMANN, K. CAMPBELL, J. LAI (<i>Baltimore; College Park, MD; Sacramento, CA, USA</i>)	2225
Ultrasound-guided Interfascial Plane Blocks for Non-anesthesiologists in Breast Cancer Surgery: Functional Outcomes and Benefits. A. GRASSO, P. ORSARIA, F. COSTA, V. D'AVINO, E. CAREDDA, A. HAZBOUN, R. CARINO, G. PASCARELLA, M. ALTOMARE, O.C. BUONOMO, F.E. AGRÒ, V. ALTOMARE (<i>Rome; Milan, Italy</i>)	2231
Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. M. TONE, M. INOMATA, N. AWANO, N. KUSE, T. JO, H. YOSHIMURA, J. MINAMI, K. TAKADA, S. MIYAMOTO, T. IZUMO (<i>Tokyo, Japan</i>)	2239
Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. K. KATO, Y. NARITA, S. MITANI, K. HONDA, T. MASUISHI, H. TANIGUCHI, S. KADOWAKI, T. URA, M. ANDO, M. TAJIKA, K. MURO (<i>Aichi; Osaka; Chiba; Kyoto, Japan</i>)	2247
An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer. D. RADES, T. NGUYEN, S. JANSSEN, S.E. SCHILD (<i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i>)	2257
Remaining Lifespan of Patients Aged ≥ 65 Years Receiving Whole-brain Irradiation for Metastases from Cancer of Unknown Primary. D. RADES, T. NGUYEN, M.T. KHOA, S. JANSSEN, S.E. SCHILD (<i>Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i>)	2261
Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report. D. SCHALLIER, P. LESFEVRE, H. EVERAERT (<i>Brussels, Belgium</i>).....	2265
Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast. D. RADES, T. NGUYEN, S. JANSSEN, M.T. KHOA, S.E. SCHILD (<i>Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i>)	2271
Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer. Y. SHIMODA, T. YAMADA, K. KOMORI, H. WATANABE, H. OSAKABE, K. KANO, H. FUJIKAWA, T. HAYASHI, H. CHO, M. SHIOZAWA, T. YOSHIKAWA, S. MORINAGA, Y. OTA, K. KATSUMATA, A. TSUCHIDA, T. OGATA, T. OSHIMA (<i>Yokohama; Tokyo, Japan</i>).....	2275
Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. T. KUZUYA, M. ISHIGAMI, T. ITO, Y. ISHIZU, T. HONDA, T. ISHIKAWA, M. FUJISHIRO (<i>Nagoya, Japan</i>).....	2283

Impact of Bevacizumab <i>Versus</i> Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group. G. MOUNTZIOS, X. MAVROPOULOU, G.-A. KOLIOU, H. LINARDOU, E. SAMANTAS, P. KOSMIDIS, G. FOUNTZILAS, A. CHARITANDI, A. KALOGERA-FOUNTZILA (<i>Athens; Thessaloniki, Greece; Limassol, Cyprus</i>).....	2095
Textbook Outcomes Among Patients Undergoing Retroperitoneal Sarcoma Resection. D. MORIS, M. CERULLO, D.P. NUSSBAUM, D.G. BLAZER 3rd (<i>Durham, NC, USA</i>).....	2107
Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients. T.K. EGGERSMANN, P. BAUMEISTER, J. KUMBRINK, D. MAYR, E. SCHMOECKEL, C.J. THALER, C. DANNECKER, U. JESCHKE, T. NAGLER, S. MAHNER, K. SHARAF, J.K.S. GALLWAS (<i>Munich; Augsburg; Goettingen, Germany; Leiden, the Netherlands</i>).....	2117
Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer. M. MÜLLER, U. GÜTH, Z. VARGA, K. REEVE, V. BJELIC-RADISIC, M. FLEISCH, C.J. TAUSCH, C. ELFGEN (<i>Zurich, Switzerland; Wuppertal; Witten-Herdecke, Germany</i>).....	2125
EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma. H. NAKAYAMA, K. KAWACHI, N. SUGANUMA, T. YOSHIDA, T. YAMASHITA, T. YAMANAKA, Y. MATSUBARA, K. KOHAGURA, S. TODA, Y. NAKAMURA, Y. MIYAGI, Y. RINO, M. MASUDA (<i>Yokohama, Japan</i>).....	2133
Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes. R. FUKUI, Y. FUJIMOTO, T. WATANABE, N. INOUE, A. BUN, T. HIGUCHI, M. IMAMURA, K. MORIMOTO, S. HIROTA, Y. MIYOSHI (<i>Nishinomiya; Hyogo; Osaka; Saitama, Japan</i>).....	2141
Outcome in Patients Treated With Cytoreductive Surgery and HIPEC for Gastric Cancer With Peritoneal Carcinomatosis. F. BRAEUER, I. FISCHER, L. BRAMMEN, G. PRESSL, R. FUEGGER, K. ROHREGGER, H. WUNDSAM (<i>Linz; Vienna, Austria</i>).....	2151
Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab. L. SIMETIĆ, K. BLAŽIČEVIĆ, K. MEĐUGORAC, M. GOLČIĆ, D. HERCEG (<i>Zagreb; Rijeka, Croatia</i>).....	2157
Outcomes of Laparoscopic Surgery in Colorectal Cancer Patients With Dialysis. N. HIGASHINO, T. MATSUDA, H. HASEGAWA, K. YAMASHITA, H. SAKAMOTO, M. FUJIKAWA, M. YAMAMOTO, S. KANAJI, T. OSHIKIRI, T. NAKAMURA, S. SUZUKI, Y. KAKEJI (<i>Kobe, Japan</i>).....	2165
Nomogram for Predicting the Pathological Tumor Response from Pre-treatment Clinical Characteristics in Rectal Cancer. B.-H. KANG, C. SONG, S.-B. KANG, K.-W. LEE, H.S. LEE, J.-S. KIM (<i>Seoul; Seongnam, Republic of Korea</i>).....	2171
Comparison of Patient Satisfaction on a Day-case Mastectomy Pathway for Breast Cancer <i>Versus</i> a Traditional Inpatient Delivery Model, Using a Validated Questionnaire. S. DAVEY, A. ROCHE, I. PEGBA-OTEMOLU, A. IBRAHIM, R. AINSWORTH (<i>Bristol; Livingston; Oxford, East Grinstead, UK</i>).....	2179
Correlation of Ductoscopic and Histopathological Findings and Their Relevance as Predictors for Malignancy: A German Multicenter Study. R. OHLINGER, C. FLIEGER, W. HAHNDORF, S. PAEPKE, J.-U. BLOHMER, S. GRUNWALD, Z. ALWAFI, R. FLIEGER, O. CAMARA, U. DEICHERT, U. PEISKER, T. KOHLMANN, I. BUCHHOLZ, K. HEGENSCHIED, K. UTPATEL, A. STOMPS, U. RECHENBERG, M. ZYGMUNT, M. HAHN (<i>Greifswald; Munich; Berlin; Jena; Cuxhaven; Erkelenz; Tuebingen, Germany</i>).....	2185
Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study. A. GADDUCCI, E. SIMONETTI, G. MANCA, F. GUIDOCCIO, A. FANUCCHI, S. COSIO, D. VOLTERRANI (<i>Pisa, Italy</i>).....	2191

Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer. S.Y. PARK, J.K. LEE, M.H. PARK, K.-Y. JEONG, H.M. KIM (<i>Incheon, Republic of Korea</i>).....	1989
The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy. W. JELSKI, J. PIECHOTA, K. ORYWAL, B. MROCZKO (<i>Bialystok; Warsaw, Poland</i>).....	1997
Association Between <i>MMP8</i> Gene Polymorphisms and Laryngeal Squamous Cell Carcinoma. R. INSODAITE, V. LIUTKEVICIUS, V. ULOZA, R. SOLOVEJUTE, A. SMALINSKIENE (<i>Kaunas, Lithuania</i>).....	2003
Association of Nijmegen Breakage Syndrome 1 Genotypes With Bladder Cancer Risk. M. CHEN, W.-S. CHANG, T.-C. SHEN, C.-L. GONG, M.-L. LIN, Z.-H. WANG, Y.-C. WANG, C.-H. CHEN, H.-C. WU, D.-T. BAU, C.-W. TSAI (<i>Beijing, PR China; Taichung, Taiwan, ROC</i>).....	2011
Alteration of Cell Surface Markers CD38 and CD138 in Lymphoproliferative Disorders in the Ocular Adnexa. Y. SUIMON, S. KASE, I. MIURA, K. ISHIJIMA, S. ISHIDA (<i>Sapporo; Obihiro, Japan</i>).....	2019
Grape Stem Extracts From Three Native Greek Vine Varieties Exhibit Strong Antioxidant and Antimutagenic Properties. A.S. VESKOUKIS, E. VASSI, K. POULAS, M. KOKKINAKIS, E. ASPRODINI, S. HAROUTOUNIAN, D. KOURETAS (<i>Larissa; Patras; Heraklion; Athens, Greece</i>).....	2025
SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells. J. LEE, G. SEO, W. HUR, S.K. YOON, S.W. NAM, J.-H. LEE (<i>Seoul, Republic of Korea</i>).....	2033
<i>Clinical Studies</i>	
B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate. Y.N. TU, W.L. TONG, B.M. CALLAHAN, B.I. CHOBRUTSKIY, G. BLANCK (<i>Tampa, FL, USA</i>).....	2043
Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial. R. NAKAMURA, T. HIRATA, O. SUZUKI, K. OTANI, N. KAI, K. HATANO, K. FUJITA, M. UEMURA, R. IMAMURA, K. TANAKA, Y. YOSHIOKA, N. NONOMURA, K. OGAWA (<i>Osaka; Tokyo, Japan</i>).....	2053
Prolonged Steroid Dependence in Adult Patients With Glioma. E.C. MANTILLA Jr., J. ABRAMOWITZ, T. DAN, E. PAN (<i>Fort Worth; Dallas, TX, USA</i>).....	2059
Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors. T. YAMAMOTO, Y. NIIBE, Y. MATSUMOTO, Y. DEKURA, R.-J. OH, H. YAMASHITA, H. KAKUHARA, M. AOKI, K. JINGU (<i>Sendai; Tokyo; Okayama; Niigata; Sapporo; Osaka; Morioka; Hirosaki, Japan</i>).....	2065
Diagnostic Value of FDG-PET/CT for the Identification of Extranodal Extension in Patients With Head and Neck Squamous Cell Carcinoma. R. TOYA, T. SAITO, T. MATSUYAMA, Y. KAI, S. SHIRAISHI, D. MURAKAMI, R. YOSHIDA, T. WATAKABE, F. SAKAMOTO, N. TSUDA, H. ARIMURA, Y. ORITA, H. NAKAYAMA, N. OYA (<i>Kumamoto; Fukuoka, Japan</i>).....	2073
Predicting Difficult Laparoscopic Total Mesorectal Excision for Locally-advanced Mid-low Rectal Cancer: The <i>EuMaRCS</i> Score Validation. N. de'ANGELIS, A. MARTÍNEZ-PÉREZ, G.C. VITALI, F. PIGNEUR, A. LUCIANI, F. BRUNETTI, M. KRAFT, E. MARTÍ-MARTÍNEZ, P. MORONI, E. ESPIN, F. RIS, S. PUCCIARELLI (<i>Créteil, France; Valencia; Barcelona, Spain; Geneva, Switzerland; Padua, Italy</i>).....	2079
Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. T. KUZUYA, M. ISHIGAMI, T. ITO, Y. ISHIZU, T. HONDA, T. ISHIKAWA, M. FUJISHIRO (<i>Nagoya, Japan</i>).....	2089

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers. T.-T. LUU, D.-H. BACH, D. KIM, R. HU, H.J. PARK, S.K. LEE (<i>Seoul, Republic of Korea</i>)	1855
Hypoxia Inducible Factor-1 α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells. T. SHUKUYA, J. OYANAGI, M. SERIZAWA, M. WATANABE, N. YAMAMOTO, Y. KOH (<i>Shizuoka; Tokyo; Wakayama, Japan</i>)	1867
Detection of Mediastinal Lymph Node Metastases Using Indocyanine Green (ICG) Fluorescence Imaging in an Orthotopic Implantation Model. S. ZHAO, X. GUO, M. TANIGUCHI, K. KONDO, S. YAMADA, C. GU, H. URAMOTO (<i>Liaoning, PR China; Ishikawa; Tokushima, Japan</i>)	1875
Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer. H. LEE, M. LEE, J.-H. SEO, G. GONG, H.J. LEE (<i>Seoul, Republic of Korea</i>)	1883
Comparison of Strength of Anastomosis Between Four Different Techniques for Colorectal Surgery. K. TOMORI, K. ETO, K. HARUKI, H. SUGANO, Y. IMAIZUMI, T. KUMAMOTO, N. TAKADA, Y. SHIMOYAMA, K. YANAGA (<i>Tokyo, Japan</i>)	1891
Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer. H.-B. KIM, H.-J. LEE, G.-B. KIM, H.-J. LIM, J.H. PARK, S.-G. PARK (<i>Gwangju, Republic of Korea</i>).....	1897
Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G ₂ /M Cell-cycle Arrest and Intrinsic Cell Death Pathway. D.H. KIM, N. SP, D.Y. KANG, E.S. JO, A. RUGAMBA, K.-J. JANG, Y.M. YANG (<i>Seoul, Republic of Korea</i>)	1905
A New Model Applied for Evaluating a Rhenium-diselenium Drug: Breast Cancer Cells Stimulated by Cytokines Induced from Polynuclear Cells by LPS. V. VEENA, A. HARIKRISHNAN, B. LAKSHMI, S. KHANNA, D. DESMAELE, P. COLLERY (<i>Bangalore; Chennai; Mumbai, India; Châtenay-Malabry; Algajola, France</i>)	1915
Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma. M. TAKAHASHI, K. FUKUDA, Y. SAIKAWA, R. NAKAMURA, N. WADA, H. KAWAKUBO, H. TAKEUCHI, Y. KITAGAWA (<i>Tokyo; Hamamatsu, Japan</i>).....	1921
ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas – A Clinicopathological Perspective. M. KACZOROWSKI, P. BIECEK, P. DONIZY, M. PIENIĄŻEK, R. MATKOWSKI, A. HAŁOŃ (<i>Wroclaw; Warsaw; Opole, Poland</i>)	1931
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma. Y. SEKINO, T. HAGURA, X. HAN, T. BABASAKI, K. GOTO, S. INOUE, T. HAYASHI, J. TEISHIMA, M. SHIGETA, D. TANIYAMA, K. KURAOKA, K. SENTANI, W. YASUI, A. MATSUBARA (<i>Hiroshima; Kure, Japan</i>).....	1943
Knockdown of CARD14 Inhibits Cell Proliferation and Migration in Breast Cancer Cells. J.-Y. LIM, S.W. KIM, B. KIM, S.-J. PARK (<i>Gwangju, Republic of Korea</i>)	1953
Menadione/Ascorbate Induces Overproduction of Mitochondrial Superoxide and Impairs Mitochondrial Function in Cancer: Comparative Study on Cancer and Normal Cells of the Same Origin. S. SEMKOVA, Z. ZHELEV, T. MILLER, K. SUGAYA, I. AOKI, T. HIGASHI, R. BAKALOVA (<i>Chiba, Japan; Sofia; Stara Zagora, Bulgaria; San Diego, CA, USA</i>).....	1963
Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b). M. MASIUK, M. LEWANDOWSKA, E. DOBAK, E. URASINSKA (<i>Szczecin, Poland</i>)....	1973
Experimental Animal Model of Re-irradiation to Evaluate Radiation-induced Damage in the Normal Intestine. H. DOI, M. TAMURA, K. NAKAMATSU, H. MONZEN, Y. NISHIMURA (<i>Osaka, Japan</i>)	1981